Drugs / Lisafotoclax
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07505160 | Mar 2026 → Mar 2028 expected | acute myeloid leukemia | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lisafotoclax | “Efficacy and Safety of Lisafotoclax Plus Decitabine and Homoharringtonine in Venetoclax/Azacitidine Pretreated AML Patients” NCT07505160 ↗ |
| Action | Inhibit | “BCL-2 inhibitor” NCT07505160 ↗ |
| Route | Oral | “Participants will receive oral Lisafotoclax” NCT07505160 ↗ |
| Target | BCL2 | “BCL-2 inhibitor” NCT07505160 ↗ |